欧盟GMP中英文对照.ppt
《欧盟GMP中英文对照.ppt》由会员分享,可在线阅读,更多相关《欧盟GMP中英文对照.ppt(168页珍藏版)》请在三一办公上搜索。
1、2023年6月22日,Pharmaceutical Services Corporation美国医药服务有限公司,How GMPs are regulated in Europe欧洲药品生产管理规范,What Is GMP?什么是GMP?,Definition:定义:The part of Quality Assurance which ensures products are consistently produced and controlled in accordance with the quality standards appropriate for their intended
2、use 质量保证的一部分,它确保按产品预定用途持续稳定地控制生产,保证产品符合质量标准要求。,2,What Is GMP?什么是GMP?,The procedures employed to ensure that the drug product or substance is manufactured under a quality management system and meets the claimed requirements for purity,identity,safety and quality 遵循标准操作规程,以确保药品的生产在质量管理系统的控制中并符合注册的纯度、鉴
3、别、安全和质量Continuously evolving“feasible and valuable”industry practices designed to ensure the above 持续地发展“可行性和有用性”的工业规范,以确保达到以上要求,3,A Brief History of GMPGMP历史简介,1962 The food drug and cosmetic act requires that drugs must be made in accordance with good manufacturing practices 食品、药品和化妆品法要求药品必须符合药品生产
4、管理规范1969 WHO publishes Good Practices in the Manufacture and Quality control of drugs 世界卫生组织出版了药品生产和质量控制的管理规范1971 The guide to good pharmaceutical manufacturing practice(orange guide)published 药品生产管理规范指南(orange guide)出版英国GMP1976 FDA publishes proposed cGMPS 美国食品药物管理局出版了提议的药品生产管理规范,4,A Brief History
5、of GMPGMP历史简介,1978 Major revision in FDA 21 CFR 210 and 211.美国食品药物管理局的21 CFR 210 和 211重大版本变更1989 European guide to GMP published 欧盟出版药品生产管理规范指南1991 European commission adopts two directives on principles and guidelines for GMP 欧洲委员会在药品生产管理规范原则和指南上采用两种条令1992 European guide to GMP revised.Further anne
6、xes added.Some Chapters revised 2008 欧洲药品生产管理规范指南更新,添加了新的附录。2008 年更新了一些章节。2003 Commission Directive replaced by 2003/94/EC 欧洲委员会条令由2003/94/EC取代,5,GMP VariationsGMP的差异,The overall principles of Good Manufacturing Practice are similar whether we follow the WHO Guidelines,the EU Guidelines or the FDA g
7、uidelines 不管是世界卫生组织指南、欧洲指南,还是美国食品药物管理局指南,药品生产管理规范的总体原则是相似的There are numerous variations in the application of these principles 这些原则在应用上有些差异The enforcement of the guidelines varies between different regulatory authorities 不同法规组织在指南的实施上存在差异The approach taken by individual inspectors varies 不同检查人员所采用的方
8、法存在差异The approach taken by different regulatory authorities varies 不同法规组织所采用的方法存在差异,6,The GMPs tell us what to do,they do not tell us how to do it.药品生产管理规范告诉我们做什么,而不告诉我们怎样做。How comes from:怎样来源于:industry standard practice and guidelines 工业标准规范和指南,7,Commission Directive 2003/94/EC委员会条令2003/94/EC,Repla
9、ced original directive 91/356/EEC 替代原有条令91/356/EECLays down principles and guidelines of GMP for medicinal products for human use 规定了人用药品的生产管理规范的原则和指南Member states must ensure respect for GMP by means of repeated inspections 通过反复检查,成员国必须确保遵守药品生产管理规范Interpretation of Principles and guidelines shall b
10、e by reference to the“Guide for good manufacturing practice for medicinal products and for investigational medicinal products”原则和指南的解释应参考“药品和在研药品的生产管理规范指南”,8,Commission Directive 2003/94/EC委员会条令2003/94/EC,For products imported from third country,the importer shall ensure products are manufactured to
11、 a standard at least equivalent to GMP as laid down by EU 由第三国进口的药品,进口商要确保药品的生产达到至少等同于欧盟规定的药品生产管理规范Importer shall ensure that products have been manufactured by authorised manufacturers 进口商要确保药品是授权生产厂家生产的Must be manufactured in compliance with Marketing Authorisation 药品的生产必须符合药品注册批准的要求。,9,Commission
12、 Directive 2003/94/EC委员会条令2003/94/EC,The rest of the Directive briefly summarises the aspects of GMP that must be in place.These are addressed in more detail in the GMP Guide.条令的其余部分总结了药品生产管理规范必须执行的方面。这些在药品生产管理规范指南中有更详细地说明。,10,EU Guidelines to GMP欧洲GMP指南,Published as Vol 4 of EudraLex by the Europea
13、nCommission由欧洲委员会出版,共4卷。This comprises:这包括:Introduction 引言Chapter 1 Quality Management 第一章 质量管理Chapter 2 Personnel 第二章 人员Chapter 3 Premises and Equipment 第三章 厂房和设备,11,EU Guidelines to GMP欧洲GMP指南,Chapter 4 Documentation 第四章 文件Chapter 5 Production 第五章 生产Chapter 6 Quality Control 第六章 质量控制Chapter 7 Cont
14、ract Manufacturing and Analysis 第七章 外包生产和样品分析Chapter 8 Complaints and Product Recall 第八章 投诉和成品召回Chapter 9 Self Inspection 第九章 自检,12,EU Guidelines to GMP欧洲GMP指南,Annex 1 Manufacture of Sterile Medicinal Products 附录一 无菌药品的生产Annex 2 Manufacture of Biological Medicinal Products for Human Use 附录二 人用生物药品的生
15、产Annex 3 Manufacture of Radiopharmaceuticals 附录三 放射药品的生产Annex 4 Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products 附录四 非免疫动物药品的生产 Annex 5 Manufacture of Immunological Veterinary Medicinal Products 附录五 免疫动物药品的生产,13,EU Guidelines to GMP欧洲GMP指南,Annex 6 M
16、anufacture of Medicinal Gases 附录六 医用气体的生产Annex 7 Manufacture of Herbal Medicinal Products 附录七 草本药品的生产 Annex 8 Sampling of Starting and Packaging Material 附录八 原材料和包装材料的取样Annex 9 Manufacture of Liquids,Creams and Ointments 附录九 液体、乳剂和膏剂的生产Annex 10 Manufacture of Pressurised Metered Dose Aerosol Prepara
17、tions for Inhalation 附录十 压力计量喷雾状吸入式药剂的生产,14,Annex 11 Computerised Systems 附录十一 计算机系统Annex 12 Use of Ionising Radiation in the Manufacture of Medicinal Products 附录十二 药品生产过程中电离辐射的使用Annex 13 Manufacture of Investigational Medicinal Products 附录十三 研究用药品的生产Annex 14 Manufacture of Medicinal Products derive
18、d from Human Blood or Plasma 附录十四 来源于人体血液或血浆药品的生产,EU Guidelines to GMP欧洲GMP指南,15,Annex 15 Qualification and Validation 附录十五 确认和验证Annex 16 Certification by a Qualified Person and Batch Release 附录十六 药品放行责任人签发证书和放行批产品Annex 17 Parametric Release 附录十七 参数放行Annex 18 Not Used(was used for GMP for API)附录十八 未
19、使用(以前用于合成制药的生产管理规范)Annex 19 Reference and Retention samples 附录十九 对照样品和留样Annex 20 Quality Risk Management 附录二十 质量风险管理,EU Guidelines to GMP欧洲GMP指南,16,Who are the Regulators法规管理者是谁,European Medicines Agency(EMEA)欧洲药品管理局(EMEA)decentralised body of the European Union with headquarters in London.欧盟的分散机构,其
20、总部在伦敦The EMEA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products(centralised procedure).Under the centralised procedure,companies submit one single marketing authorisation application to the EMEA.EMEA负责对拟在欧洲上市的药品申请进行科学评估(集中审评)。在集中
21、审评程序下,公司要向EMEA提交单独的上市许可申请。,17,All medicinal products for human and animal use derived from biotechnology and other high-technology processes must be approved via the centralised procedure.The same applies to all human medicines intended for the treatment of HIV/AIDS,cancer,diabetes or neurodegenerat
22、ive diseases and for all designated orphan medicines intended for the treatment of rare diseases.所有由生物技术及其它高科技工艺制备的人用药品和兽药产品,都必须通过集中审评程序报批。治疗艾滋病、肿瘤、糖尿病、神经退化以及罕见病的药物,也须按照集中审评程序报批。,Who are the Regulators法规管理者是谁,18,For medicinal products that do not fall under any of the above-mentioned categories comp
23、anies can submit an application for a centralised marketing authorisation to the EMEA,provided the medicinal product constitutes,a significant therapeutic,scientific or technical innovation or the product is in any other respect in the interest of patient or animal health.对于不属于上述类型的药品,如果药效十分明显,科学或工艺
24、上有创新,或产品的其它方面对病人及动物的健康十分有益时,企业也可向EMEA递交集中审评程序的申请。,Who are the Regulators法规管理者是谁,19,For a generic,the centralised procedure can be used if the innovator product was centrally authorised 对于仿制药,如果创新药已由集中审评程序批准,那么也可以按集中审评程序申请。Responsible for coordinating GMP inspections when centralised application proc
25、ess is used.The responsibility for carrying out inspections rests with the Competent Authority under whose responsibility the manufacturer falls.当集中申请程序适用时,负责协调GMP检查。进行检查的责任取决于生产厂家隶属于哪家主管当局管辖。,Who are the Regulators法规管理者是谁,20,EMEA Coordinated GMP InspectionsEMEA 协调的GMP检查,21,22,From 1995 to 2006,a to
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 欧盟 GMP 中英文 对照

链接地址:https://www.31ppt.com/p-5286200.html